Medical Developments International Limited

ASX:MVP Stock Report

Market Cap: AU$45.6m

Medical Developments International Future Growth

Future criteria checks 4/6

Medical Developments International is forecast to grow earnings and revenue by 93.1% and 14.4% per annum respectively. EPS is expected to grow by 94.3% per annum. Return on equity is forecast to be 7% in 3 years.

Key information

93.1%

Earnings growth rate

94.3%

EPS growth rate

Pharmaceuticals earnings growth36.9%
Revenue growth rate14.4%
Future return on equity7.0%
Analyst coverage

Low

Last updated25 Oct 2024

Recent future growth updates

Recent updates

Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump

May 13
Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump

Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?

May 03
Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?

Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge

Mar 11
Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge

Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward

Jan 16
Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward

Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?

Jan 03
Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Aug 09
Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate

Apr 24
We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Jul 04
Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Mar 04
Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates

Mar 05
Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates

If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns

Feb 07
If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns

Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)

Dec 16
Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)

Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Dec 10
Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Earnings and Revenue Growth Forecasts

ASX:MVP - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2027554471
6/30/2026480571
6/30/202541-4131
6/30/202433-41-14-11N/A
3/31/202433-30-17-12N/A
12/31/202334-19-21-15N/A
9/30/202333-12-23-16N/A
6/30/202332-6-24-16N/A
3/31/202329-4-22-16N/A
12/31/202226-2-20-15N/A
9/30/202224-7-18-13N/A
6/30/202222-12-16-11N/A
3/31/202222-16-17-10N/A
12/31/202122-19-17-10N/A
9/30/202124-16-16-9N/A
6/30/202125-13-15-9N/A
3/31/202125-7-14-8N/A
12/31/202024-1-13-6N/A
9/30/2020230-11-3N/A
6/30/2020230-90N/A
3/31/2020221-81N/A
12/31/2019221-81N/A
9/30/2019221211N/A
6/30/20192111121N/A
3/31/20192011222N/A
12/31/20181901223N/A
9/30/2018180212N/A
6/30/2018170-92N/A
3/31/2018181N/A2N/A
12/31/2017182N/A3N/A
9/30/2017182N/A3N/A
6/30/2017182N/A4N/A
3/31/2017182N/A4N/A
12/31/2016182N/A4N/A
9/30/2016172N/A8N/A
6/30/2016152N/A12N/A
3/31/2016141N/A12N/A
12/31/2015121N/A13N/A
9/30/2015121N/A8N/A
6/30/2015122N/A3N/A
3/31/2015111N/A3N/A
12/31/2014101N/A3N/A
9/30/2014101N/A2N/A
6/30/201491N/A1N/A
3/31/2014101N/A1N/A
12/31/2013101N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MVP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: MVP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MVP is expected to become profitable in the next 3 years.

Revenue vs Market: MVP's revenue (14.4% per year) is forecast to grow faster than the Australian market (5.8% per year).

High Growth Revenue: MVP's revenue (14.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MVP's Return on Equity is forecast to be low in 3 years time (7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 19:04
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medical Developments International Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Anubhav SaxenaBell Potter
Martyn JacobsCanaccord Genuity